新闻中心

News Center

Home page

All Categories



Company News

Industry News

Foncoo Pharmaceutical successfully introduced [Olanzhi] Olanzapine Tablets

Release Time

2022-06-21 15:32

On September 23, 2013, Foncoo Pharmaceutical officially signed an agency agreement for psychoactive products with Dr. Reddy Laboratories Co., Ltd. of India, and successfully introduced [Olanzhi] Olanzapine Tablets (5mg and 10mg). Olanzapine Tablets is a first-line drug for the treatment of schizophrenia, with a large market capacity and excellent prospects.

[Olanzhi] Olanzapine Tablets are produced by Dr. Reddy Laboratories Ltd., the second largest pharmaceutical company in India. [Olanzhi] is an EU-certified product and has been marketed in the United States (the first imitation product), the United Kingdom, Switzerland, Australia, Italy, Brazil, and Singapore. It has obtained good clinical feedback in the treatment of schizophrenia and bipolar affective disorder. [Olanzhi] is an EU-quality product with Chinese prices, fully in line with modern pharmacoeconomics, and is the best olanzapine for cost-effectiveness analysis.

Hiking from Huaying Ancient, passing through rural bamboo forests

无

Hiking from Huaying Ancient, passing through rural bamboo forests

无

Related News

Foncoo Pharmaceutical participated in the 19th National Psychiatry Academic Conference of the Chinese Medical Association

Sponsored by the Chinese Medical Association and the Psychiatry Branch of the Chinese Medical Association, and organized by the Chongqing Medical Association, the Psychiatry Branch of the Chongqing Medical Association, the First Affiliated Hospital of Chongqing Medical University, and the University City Hospital Affiliated to Chongqing Medical University The conference and the Academic Conference on Child and Adolescent Psychiatry were successfully held at Chongqing Yuelai International Conference Center from December 21 to 24, 2021.

2022-05-25

2021-Foncoo Public Welfare

On October 15, 2021, Foncoo Pharmaceutical donated 100,000 yuan in cash to the "Gu Xueqiu Pharmacy Education Fund" public welfare student aid project of the Beijing Renren Public Welfare Foundation-Shenyang Pharmaceutical University.

2022-05-25

Foncoo Pharmaceutical's corporate culture 5.0 was officially released

Official announcement! Seriously, don't be distracted!

2022-05-25

Foncoo Pharmaceutical participated in the 16th National Academic Conference on Psychiatric Hospital Management

On October 29-31, 2021, the 16th National Academic Conference on Psychiatric Hospital Management, hosted by the Chinese Hospital Association and the Chinese Hospital Association Psychiatric Hospital Branch, was held in Chongqing.

2022-05-25

"Bupropion Hydrochloride Sustained-Release Tablets (II)" exclusively sold by Foncoo Pharmaceuticals was approved in China

Recently, "Bupropion Hydrochloride Sustained-Release Tablets (II) (150mg, 300mg)", exclusively sold by Pangu Pharmaceuticals (Mainland China), was approved by the State Drug Administration and deemed to have passed the consistency evaluation. The product, developed by Shanghai Xuantai Pharmaceuticals, was previously approved by the FDA in August 2017 and was marketed in the United States.

2022-05-25

Foncoo Pharmaceutical participated in the 9th China Schizophrenia Forum

From October 22 to 24, 2021, the "Ninth China Schizophrenia Forum" was grandly held in Wuhan. The theme of this forum is "Infection, Inflammation and Schizophrenia".

2022-05-25

0755-82873500

Room 1502-1506, Building D2, Nanshan iPark, No.1001 Xue Yuan Boulevard, Nanshan District, Shenzhen, China.

0755-82873510

京ICP备10002622号-38

0755-82873500

0755-82873510